Research programme: hepatitis B virus therapeutics - AiCuris

Drug Profile

Research programme: hepatitis B virus therapeutics - AiCuris

Latest Information Update: 26 Jan 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer AiCuris
  • Class Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 25 Jan 2016 Early research in Hepatitis B in Germany (unspecified route) (AiCuris pipeline; January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top